Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Myeloid neoplasms with eosinophilia and abnormalities of the PDGFRA gene can benefit from therapy with tyrosine kinase inhibitors, therefore revealing the PDGFRA rearrangement is essential to ensure the best choice of treatment.
|
31450116 |
2019 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
The transcript of FIP1L1-PDGFRA fusion gene is a genetic biomarker of clonal eosinophilia screened routinely by reverse transcript PCR (RT-PCR) during diagnosis.
|
30359545 |
2019 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
A thorough step-wise patient's evaluation led to identify the clonal nature of eosinophilia and the diagnosis of myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA was made.
|
31744552 |
2019 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Molecular studies were negative for Fip1-like1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) translocation and PDGFRB and FGFR mutations, indicating nonclonal eosinophilia.
|
29714651 |
2018 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement.
|
29310833 |
2018 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Findings from our institutional experience support initial testing in isolated eosinophilia with otherwise unremarkable BM to include PDGFRA rearrangement, tryptase/CD25 immunohistochemistry, cytogenetics, and T-cell flow cytometry/receptor gene rearrangement.
|
30032299 |
2018 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The patient was diagnosed with a myeloproliferative neoplasm with eosinophilia and FIP1L1-PDGFRα rearrangement after a bone marrow evaluation revealed hypercellular marrow with eosinophilia and fluorescence in situ hybridization identified the FIP1L1-PDGFRα rearrangement.
|
30184522 |
2018 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
We describe identification of a FIP1L1-PDGFRA fusion in a 13-year-old boy who presented with T-lymphoblastic leukemia/lymphoma without eosinophilia.
|
29025601 |
2017 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The purpose of this review is to provide an overview of the differential diagnosis for eosinophilia, to recommend specific steps for the pathologist evaluating blood and bone marrow, and to emphasize 2 important causes of eosinophilia that require specific ancillary tests for diagnosis: myeloproliferative neoplasm with PDGFRA rearrangement and lymphocyte-variant hypereosinophilic syndrome.
|
27684977 |
2016 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Given the distinct clinical and pathological characteristics, we believe that hematological neoplasms harboring BCR-JAK2 should be included as an additional distinct entity to the current WHO category of "myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR", and testing for a JAK2 fusion should be pursued in neoplasms with a karyotypic 9p24 abnormality.
|
27134074 |
2016 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
|
26666578 |
2016 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The myeloid and lymphoid neoplasms with eosinophilia and PDGFRA gene rearrangements usually show a good response to Imatinib and are typically associated with a normal karyotype, occasionally exhibiting a secondary chromosomal abnormality associated with clonal evolution.
|
26191303 |
2015 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Examination for the common eosinophilia-related cytogenetic abnormalities involving the genes PDGFRA, PDGFRB, and FGFR1 together with BCR-ABL fusion gene was negative.
|
25962659 |
2015 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We present the first case of T acute lymphoblastic leukemia with a t(4;22)(q12;q11.2) involving the BCR and PDGFRA genes, without associated eosinophilia.
|
26095243 |
2015 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
This is the seventh fusion gene involving PDGFRA in MPN with eosinophilia.
|
26319757 |
2015 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To assess the presence of genetic imbalances in patients with myeloproliferative neoplasms (MPNs), 38 patients with chronic eosinophilia were studied by array comparative genomic hybridization (aCGH): seven had chronic myelogenous leukaemia (CML), BCR-ABL1 positive, nine patients had myeloproliferative neoplasia Ph- (MPN-Ph-), three had a myeloid neoplasm associated with a PDGFRA rearrangement, and the remaining two cases were Lymphoproliferative T neoplasms associated with eosinophilia.
|
24813417 |
2014 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The presence of a dominant neoplastic clone with FIP1L1-PDGFRA rearrangement was suspected on the basis of sudden onset of peripheral and bone marrow eosinophilia and confirmed by fluorescence in situ hybridization and molecular diagnostic tests.
|
24669761 |
2014 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, elevated expression of Hes1 was found in two of five samples of Fip1-like1 platelet-derived growth factor receptor-α (FIP1L1-PDGFA)-positive myeloid neoplasms associated with eosinophilia.
|
24486648 |
2014 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
The fusion product of such genes is a tyrosine kinase oncoprotein sensitive to imatinib, which to date results to be the standard of care for FIP1L1-PDGFRA-positive chronic myeloproliferative disorders with eosinophilia.
|
24460680 |
2014 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Rearrangement of the PDGFRA gene defines a distinct group of hematopoietic neoplasms that commonly present with persistent eosinophilia and are highly sensitive to low-dose imatinib mesylate treatment.
|
23232855 |
2013 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
|
23489324 |
2013 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
|
23400675 |
2013 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, after treatment with hydroxyurea and serial phlebotomies had been started, the patient developed hypereosinophilia, fitting the category of a myeloproliferative neoplasm with eosinophilia associated with the FIP1L1-PDGFRA gene fusion, as confirmed by molecular analysis.
|
22944561 |
2012 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with FIP1L1-PDGFRA fusion presented with more bone marrow eosinophils and peripheral blood eosinophilia as well as anemia, leukocytosis and thrombocytopenia.
|
22806436 |
2012 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.
|
21641642 |
2011 |